Eliaz Therapeutics
Eliaz Therapeutics is a pre-revenue clinical-stage medical device company developing XGAL-3, an extracorporeal apheresis device that selectively removes Galectin-3 from the bloodstream to treat sepsis and other inflammatory conditions in hospital ICU settings.
- Company typePrivate
- Founded2022
- HeadquartersSanta Rosa, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Eliaz Therapeutics does
Eliaz Therapeutics Inc. is a privately held, clinical-stage medical device company developing XGAL-3 (XGal-3), an extracorporeal therapeutic apheresis device designed to selectively remove Galectin-3 from the bloodstream of ICU sepsis patients. The device consists of a proprietary antibody-coated immuno-affinity resin column that integrates with the Terumo Spectra Optia apheresis system; blood is processed outside the body, Galectin-3 is captured by the column, and filtered blood is returned to the patient without the introduction of drugs or biologic agents. The company is headquartered in Santa Rosa, California, employs 1-10 people, and operates under an exclusive global collaboration with Terumo Blood and Cell Technologies announced in July 2022.
Eliaz's commercial strategy targets hospital intensive care units treating sepsis, a condition with 1.7M US hospitalizations and 350K US deaths annually and no FDA-approved direct treatment. The planned revenue model is hardware sales of the XGal-3 device plus recurring single-use column disposables to hospitals, with the company projecting 75-80% gross margins against ICU stay costs exceeding $36,000 per patient. The company has been awarded FDA Breakthrough Device Designation for sepsis (March 2025) and holds 75+ issued patents across 30+ countries. Capitalization to date totals approximately $14M+ across a $1.9M NIH grant program, $850K in SAFEs from accredited investors, and approximately $11.8M from crowdfunding investors via Regulation Crowdfunding and Regulation D offerings processed through DealMaker Securities, with a current pre-money valuation of $59.4M.
Beyond the lead sepsis indication, Eliaz is positioning XGal-3 as a platform technology with potential application in oncology, fibrosis, heart disease, chronic kidney disease, and viral infections, leveraging a modular column architecture and a pending patent family covering expanded therapeutic uses. Distribution post-approval is expected to flow through Terumo BCT's installed apheresis base across nearly 200 countries. The company is pre-revenue, pre-FDA approval, and currently raising capital to fund GLP safety studies and first-in-human clinical trials.
Eliaz Therapeutics firmographics
Firmographics- Name
- Eliaz Therapeutics
- Legal name
- Eliaz Therapeutics Inc.
- Website
- https://eliaztherapeutics.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Eliaz Therapeutics is a pre-revenue clinical-stage medical device company developing XGAL-3, an extracorporeal apheresis device that selectively removes Galectin-3 from the bloodstream to treat sepsis and other inflammatory conditions in hospital ICU settings.
- Ownership category
- akta.pro rank
Eliaz Therapeutics industry classification
Industry- Product category
- Therapeutic Apheresis Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Plasma-Derived Therapy Quality, Safety & Pharmacovigilance (Pathogen Reduction/Testing) (HLAIAHAK)
Keywords
Where Eliaz Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Santa Rosa
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Eliaz Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Marketing or Sales, Personnel, Infrastructure
Revenue model
- Medical Device Sales: Once FDA approved, the company plans to commercialize the XGal-3 apheresis device for use in ICU settings treating sepsis patients. Revenue will be generated through device sales and disposables (columns) to hospitals. The company projects 75-80% gross margin with cost of ICU stay exceeding $36,000 per patient.
- Regulation Crowdfunding Investment Rounds: The company raises equity capital through Regulation Crowdfunding offerings, selling common stock to retail investors via the DealMaker platform. Currently raising $3M to support GLP safety studies and first-in-human trials.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Minimum Investment - Equity Crowdfunding |
| One time/ perpetual license | Pay-as-you-go | Reg D Accredited Investor Offering |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels7 records
Eliaz Therapeutics product offering
Product offeringCore offering
Eliaz Therapeutics is developing XGAL-3 (XGal-3), an investigational extracorporeal therapeutic apheresis device that selectively removes Galectin-3 from patient blood plasma using a proprietary antibody-coated immuno-affinity resin column. The single-use column is designed to connect with existing hospital apheresis machines (Terumo Spectra Optia) and is initially targeted at ICU sepsis treatment, with potential platform expansion to fibrosis, oncology, and kidney disease.
Product overview
Eliaz Therapeutics is a clinical-stage medical device company developing a single targeted apheresis platform, XGAL-3 (XGal-3), designed to selectively remove Galectin-3 from the bloodstream. The XGAL-3 device is an investigational extracorporeal therapy consisting of a proprietary antibody-coated resin column that integrates with existing hospital apheresis machines (specifically the Terumo Spectra Optia system). The platform targets Galectin-3, a protein implicated in sepsis, inflammation, fibrosis, cancer, and organ failure, positioning the technology as both a standalone treatment and a potential platform for multiple inflammatory conditions.
Differentiator
Problem solved
Functional benefit
Brands
- XGal-3: Patented investigational apheresis device designed to selectively remove Galectin-3 from the bloodstream for treatment of sepsis and other inflammatory conditions.
Products and services
- XGAL-3 (XGal-3) Apheresis Device An advanced extracorporeal therapeutic apheresis medical device designed to selectively remove Galectin-3 from the bloodstream of sepsis patients in hospital ICUs. The device uses a proprietary antibody-based resin column that binds and removes Galectin-3 during blood processing outside the body, integrating with the installed Terumo Spectra Optia apheresis platform and intended as a single-use cartridge for early ICU intervention alongside standard critical care.
Quantifiable outcome
- In large-animal sepsis model, XGal-3 demonstrated improvements in key physiological indicators within 90 minutes
- +3 more outcomes
Companies that use Eliaz Therapeutics
Customer profileSegments4 records
Ideal customer profiles1 record
Eliaz Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
Feature5 records
Eliaz Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Terumo Blood and Cell Technologies (Terumo BCT)flagship/ coreExclusive global collaboration announced July 27, 2022 between Terumo BCT and Eliaz Therapeutics. Collaboration focuses on selective removal of Galectin-3 from blood plasma for AKI and S-AKI treatment. Uses Terumo's Spectra Optia Apheresis System with ETI's novel XGal-3 column. Terumo BCT is a global leader in blood component and apheresis technology with presence in nearly 200 countries. The partnership provides apheresis platforms and disposables for preclinical and clinical programs, enabling integration with established hospital infrastructure and clear pathway to global commercialization.
Scale indicators12 records
Recent moves6 records
Expansion highlights6 records
Eliaz Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Baxter International: Baxter's Fenwal/Amicus therapeutic apheresis systems are used in hospitals for cell and plasma collection, positioning Baxter as a broad incumbent offering overlapping apheresis infrastructure to the same hospital departments XGal-3 targets.
- Haemonetics Corporation: Haemonetics is an established incumbent in blood management and apheresis systems used in hospitals and blood centers, a comparable broad incumbent in the apheresis device category that XGal-3 enters.
- Fresenius Kabi: Fresenius Kabi manufactures apheresis and blood-collection devices distributed globally and serves ICU and hospital customers overlapping with XGal-3's apheresis-based sepsis indication.
- Terumo Blood and Cell Technologies: Terumo BCT is ETI's exclusive platform partner and the dominant incumbent in apheresis and blood-component technology, providing the Spectra Optia infrastructure that XGal-3 integrates with — directly shaping ETI's go-to-market.
Direct peers
- CytoSorbents Corporation: CytoSorbents markets CytoSorb, an extracorporeal blood-purification cartridge used in ICU settings for cytokine and inflammatory mediator removal — the closest direct functional comparable to XGal-3 for sepsis and critical-care blood filtration.
- ExThera Medical: ExThera's Seraph 100 is an extracorporeal blood-filtration device deployed in ICUs for pathogen and inflammatory mediator reduction, making it a direct apheresis-platform peer targeting similar sepsis and critical-care workflows.
- Galectin Therapeutics: Galectin Therapeutics is developing small-molecule Galectin-3 inhibitors (e.g., belapectin) for liver fibrosis and oncology, targeting the exact same Galectin-3 biology that Eliaz Therapeutics addresses via extracorporeal apheresis.
Emerging players
- Spectral Medical: Spectral Medical is pursuing endotoxin removal in septic patients via the Toraymyxin PMX column, an emerging extracorporeal therapy for sepsis that overlaps with XGal-3's targeted sepsis indication.
- Aethlon Medical: Aethlon's Hemopurifier is an extracorporeal affinity cartridge targeting viruses and immunosuppressive exosomes — a partial-overlap therapeutic apheresis platform addressing infectious and critical-care indications similar to XGal-3.
Regional players
- Innovative Renal Care: Innovative Renal Care operates a network of dialysis and apheresis service centers in the US, including Galectin-3-related therapeutic plasma exchange programs that intersect with the patient populations XGal-3 eventually targets in CKD and critical care.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Eliaz Therapeutics social profiles
Digital presenceEliaz Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Eliaz Therapeutics leadership team
Management profileNumber of profiles
Profiles8 records
Eliaz Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Eliaz Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Eliaz Therapeutics
What does Eliaz Therapeutics do?
Eliaz Therapeutics is developing XGAL-3 (XGal-3), an investigational extracorporeal therapeutic apheresis device that selectively removes Galectin-3 from patient blood plasma using a proprietary antibody-coated immuno-affinity resin column. The single-use column is designed to connect with existing hospital apheresis machines (Terumo Spectra Optia) and is initially targeted at ICU sepsis treatment, with potential platform expansion to fibrosis, oncology, and kidney disease.
Is Eliaz Therapeutics a public or private company?
Eliaz Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Eliaz Therapeutics founded?
Eliaz Therapeutics was founded in 2022. It employs 1 to 10 people.
Where is Eliaz Therapeutics based?
Eliaz Therapeutics is headquartered in Santa Rosa, United States, in the North America region.
How does Eliaz Therapeutics make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are regulation Crowdfunding Investment Rounds.
Who are Eliaz Therapeutics's main competitors?
Broad incumbents on record are Baxter International, Haemonetics Corporation, Fresenius Kabi and Terumo Blood and Cell Technologies. Direct peers are CytoSorbents Corporation, ExThera Medical and Galectin Therapeutics. Emerging players are Spectral Medical and Aethlon Medical. Innovative Renal Care is listed as a regional player.
Does Eliaz Therapeutics have an API?
No public API is recorded for Eliaz Therapeutics.
What industry is Eliaz Therapeutics in?
Eliaz Therapeutics's product category is Therapeutic Apheresis Medical Devices. Its primary akta.pro industry code is HLAIAHAK, Plasma-Derived Therapy Quality, Safety & Pharmacovigilance (Pathogen Reduction/Testing). Its NAICS code is 334510 and its SIC code is 3845.